Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DR0J | ISIN: US3621LQ1099 | Ticker-Symbol: N/A
Frankfurt
17.09.24
08:02 Uhr
6,345 Euro
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
G1 THERAPEUTICS INC Chart 1 Jahr

Aktuelle News zur G1 THERAPEUTICS

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.09.24XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 18.09.2024678The following instruments on Boerse Frankfurt do have their last trading day on 18.09.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 18.09.2024ISIN NameCA05461V2012 AXMIN...
► Artikel lesen
18.09.24Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer367- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash...
► Artikel lesen
G1 THERAPEUTICS Aktie jetzt für 0€ handeln
18.09.24XFRA G1H: AUSSETZUNG/SUSPENSION301DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILG1 THERAPEUTICS...
► Artikel lesen
05.09.24Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period204HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency...
► Artikel lesen
08.08.24G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights176- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA®...
► Artikel lesen
07.08.24Pre-market Movers: Scorpius Holdings, G1 Therapeutics, Talis Biomedical, Zhongchao, Emergent BioSolutions814OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.40 A.M. ET).In the Green G1 Therapeutics, Inc. (GTHX) is up over 66% at $7.08. Zhongchao...
► Artikel lesen
07.08.24Pharmacosmos Group to Acquire G1 Therapeutics397- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection...
► Artikel lesen
02.08.24G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)139RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable...
► Artikel lesen
24.06.24G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)271- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global...
► Artikel lesen
05.06.24G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)122RESEARCH TRIANGLE PARK, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable...
► Artikel lesen
28.05.24G1 Therapeutics: Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)180- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared...
► Artikel lesen
22.05.24G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses167RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Deimos Biosciences, a portfolio company...
► Artikel lesen
01.05.24G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 198RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable...
► Artikel lesen
01.05.24G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights136- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated...
► Artikel lesen
01.05.24G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib97RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world's first transomics drug...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten